T. Rowe Price Associates
ENTA icon

T. Rowe Price Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

T. Rowe Price Associates’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$237K Buy
18,704
+4,294
+30% +$57.6K ﹤0.01% 2774
2025
Q4 		$228K Buy
14,410
+4,264
+42% +$54.2K ﹤0.01% 2766
2025
Q3 		$122K Buy
+10,146
New +$81.1K ﹤0.01% 2892
2023
Q4 		– Sell
-11,678
Closed -$131K – 2910
2023
Q3 		$131K Buy
+11,678
New +$188K ﹤0.01% 2609
2023
Q2 		– Sell
-162,694
Closed -$6.58M – 2905
2023
Q1 		$6.58M Sell
162,694
-11,609
-7% -$554K ﹤0.01% 1124
2022
Q4 		$8.11M Sell
174,303
-66,384
-28% -$3.03M ﹤0.01% 1092
2022
Q3 		$12.5M Buy
240,687
+52,344
+28% +$3.06M ﹤0.01% 1024
2022
Q2 		$8.9M Sell
188,343
-4,716
-2% -$256K ﹤0.01% 1339
2022
Q1 		$13.7M Sell
193,059
-81,258
-30% -$5.29M ﹤0.01% 1321
2021
Q4 		$20.5M Buy
274,317
+12,194
+5% +$957K ﹤0.01% 1282
2021
Q3 		$14.9M Buy
262,123
+9,341
+4% +$462K ﹤0.01% 1365
2021
Q2 		$11.1M Sell
252,782
-611,479
-71% -$29.9M ﹤0.01% 1402
2021
Q1 		$42.6M Sell
864,261
-97,184
-10% -$4.85M ﹤0.01% 1054
2020
Q4 		$40.5M Sell
961,445
-12,984
-1% -$571K ﹤0.01% 1033
2020
Q3 		$44.6M Sell
974,429
-308,128
-24% -$14.9M 0.01% 910
2020
Q2 		$64.4M Sell
1,282,557
-72,381
-5% -$3.75M 0.01% 766
2020
Q1 		$69.7M Sell
1,354,938
-41,397
-3% -$2.21M 0.01% 685
2019
Q4 		$86.3M Sell
1,396,335
-158,917
-10% -$9.85M 0.01% 713
2019
Q3 		$93.4M Buy
1,555,252
+26,711
+2% +$1.98M 0.01% 647
2019
Q2 		$129M Buy
1,528,541
+159,504
+12% +$14.3M 0.02% 581
2019
Q1 		$131M Buy
1,369,037
+295,615
+28% +$26.5M 0.02% 567
2018
Q4 		$76M Buy
1,073,422
+10,338
+1% +$793K 0.01% 679
2018
Q3 		$90.9M Buy
1,063,084
+207,593
+24% +$20.8M 0.01% 701
2018
Q2 		$99.2M Buy
855,491
+537,087
+169% +$53.6M 0.02% 660
2018
Q1 		$25.8M Sell
318,404
-53,606
-14% -$4.13M ﹤0.01% 1096
2017
Q4 		$21.8M Buy
372,010
+269,566
+263% +$13.5M ﹤0.01% 1158
2017
Q3 		$4.79M Buy
+102,444
New +$4.12M ﹤0.01% 1444

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

T. Rowe Price Associates's ENTA Position: Q1 2026 in Review

T. Rowe Price Associates increased its Enanta Pharmaceuticals (ENTA) stake by 30% in Q1 2026, buying an estimated $57.6K and bringing the position to 18,704 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #2774.

T. Rowe Price Associates first reported a position in ENTA in Q3 2017 and has held it in 27 quarters since. The position peaked at $131M in Q1 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • T. Rowe Price Associates held 18,704 shares of Enanta Pharmaceuticals worth $237K as of Q1 2026.
  • T. Rowe Price Associates bought 4,294 Enanta Pharmaceuticals shares in Q1 2026, an estimated $57.6K.
  • Enanta Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2774 holding.
  • T. Rowe Price Associates first reported a position in Enanta Pharmaceuticals in Q3 2017 and has held it in 27 quarters since.
  • T. Rowe Price Associates's Enanta Pharmaceuticals position peaked at $131M in Q1 2019.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.